[go: up one dir, main page]

MX2016009049A - Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico. - Google Patents

Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.

Info

Publication number
MX2016009049A
MX2016009049A MX2016009049A MX2016009049A MX2016009049A MX 2016009049 A MX2016009049 A MX 2016009049A MX 2016009049 A MX2016009049 A MX 2016009049A MX 2016009049 A MX2016009049 A MX 2016009049A MX 2016009049 A MX2016009049 A MX 2016009049A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
acetic acid
composition containing
acid compound
specific compound
Prior art date
Application number
MX2016009049A
Other languages
English (en)
Inventor
Endo Yoko
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2016009049A publication Critical patent/MX2016009049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El propósito de la presente invención es proporcionar una composición farmacéutica que comprende un compuesto específico y exhibe una eficacia de conservación superior, el compuesto específico siendo estable dentro de la composición farmacéutica, y proporcionar métodos para mejorar la estabilidad del compuesto específico dentro de la composición farmacéutica y la eficacia de conservación de la composición farmacéutica. La composición farmacéutica de acuerdo a la presente invención comprende (6-{[4-(pirazol-1-il)bencil] (piridin-3-ilsulfonil)aminometil}piri din-2-ilamino)acetato de isopropilo o una sal del mismo, y además comprende ácido edético o una sal del mismo.
MX2016009049A 2014-01-10 2015-01-08 Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico. MX2016009049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014002810 2014-01-10
PCT/JP2015/050334 WO2015105135A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物含有医薬組成物

Publications (1)

Publication Number Publication Date
MX2016009049A true MX2016009049A (es) 2016-09-09

Family

ID=53523960

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003133A MX385505B (es) 2014-01-10 2015-01-08 Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
MX2016009049A MX2016009049A (es) 2014-01-10 2015-01-08 Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020003133A MX385505B (es) 2014-01-10 2015-01-08 Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico

Country Status (19)

Country Link
US (5) US10149908B2 (es)
EP (1) EP3093019B1 (es)
JP (1) JP6441087B2 (es)
KR (1) KR102281620B1 (es)
CN (1) CN105828818B (es)
AU (1) AU2015205179B2 (es)
BR (1) BR112016015909B1 (es)
CA (1) CA2935055C (es)
EA (1) EA031813B1 (es)
ES (1) ES2875307T3 (es)
GE (2) GEAP201914215A (es)
IL (1) IL246655B (es)
MX (2) MX385505B (es)
MY (1) MY179951A (es)
PH (1) PH12016501328B1 (es)
SG (1) SG11201605366QA (es)
TW (1) TWI650127B (es)
UA (1) UA121746C2 (es)
WO (1) WO2015105135A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742268T3 (es) 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
GEAP201814239A (en) 2014-01-10 2018-07-25 Santen Pharmaceutical Co Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
CN110251516B (zh) * 2014-01-10 2022-05-03 参天制药株式会社 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物
EP3320904B1 (en) 2015-07-09 2023-07-05 Santen Pharmaceutical Co., Ltd. Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure
JP6903448B2 (ja) * 2016-02-22 2021-07-14 参天製薬株式会社 ドルゾラミドとブリモニジンを含む医薬組成物
WO2018230711A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 ｍＴＯＲインヒビターを含む、眼の症状、障害または疾患を治療または予防するための医薬およびその応用
EP3639855A4 (en) 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
WO2019065838A1 (ja) 2017-09-29 2019-04-04 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
WO2019124487A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 オミデネパグの組合せ
EP3733179A4 (en) 2017-12-28 2021-09-15 Santen Pharmaceutical Co., Ltd. PHARMACEUTICAL PREPARATION CONTAINING A PYRIDYLAMINOACETIC ACID COMPOUND

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
PT1011728E (pt) 1998-07-14 2005-03-31 Alcon Mfg Ltd Recipientes de polipropileno para produtos de prostaglandina
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
JP5460996B2 (ja) * 2007-10-19 2014-04-02 大正製薬株式会社 眼科用剤
WO2009113600A1 (ja) 2008-03-12 2009-09-17 宇部興産株式会社 ピリジルアミノ酢酸化合物
HUE026742T2 (en) * 2009-03-30 2016-07-28 Ube Industries A pharmaceutical composition for the treatment or prevention of glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
JP2012180346A (ja) * 2011-02-10 2012-09-20 Santen Pharmaceut Co Ltd 親水性薬物の薬物移行性を改善した水性組成物
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
CN104136019A (zh) * 2012-02-27 2014-11-05 日本乐敦制药株式会社 眼科用组合物试剂盒
TWI723722B (zh) * 2012-03-26 2021-04-01 日商參天製藥股份有限公司 迪夸弗索鈉及依地酸鈉水合物之用途
US20150192281A1 (en) 2012-07-09 2015-07-09 Sharp Kabushiki Kaisha Light emission device, and illumination device
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
CA2878370C (en) 2012-07-13 2021-01-19 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
MX385505B (es) * 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
GEAP201814239A (en) 2014-01-10 2018-07-25 Santen Pharmaceutical Co Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
CN110251516B (zh) 2014-01-10 2022-05-03 参天制药株式会社 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物

Also Published As

Publication number Publication date
BR112016015909B1 (pt) 2020-09-29
CN105828818B (zh) 2020-06-02
US20200046839A1 (en) 2020-02-13
EA201691244A1 (ru) 2016-12-30
GEAP201914215A (en) 2019-02-25
EA031813B1 (ru) 2019-02-28
PH12016501328A1 (en) 2017-02-06
JP2015147763A (ja) 2015-08-20
EP3093019B1 (en) 2021-05-26
US20200353084A1 (en) 2020-11-12
CA2935055C (en) 2021-08-24
US10765750B2 (en) 2020-09-08
PH12016501328B1 (en) 2020-07-01
JP6441087B2 (ja) 2018-12-19
AU2015205179A1 (en) 2016-07-28
CA2935055A1 (en) 2015-07-16
AU2015205179B2 (en) 2019-09-19
IL246655A0 (en) 2016-08-31
NZ722144A (en) 2021-05-28
MY179951A (en) 2020-11-19
KR20160099582A (ko) 2016-08-22
US20240024484A1 (en) 2024-01-25
EP3093019A1 (en) 2016-11-16
GEP20196982B (en) 2019-06-25
KR102281620B1 (ko) 2021-07-23
US10485872B2 (en) 2019-11-26
UA121746C2 (uk) 2020-07-27
CN105828818A (zh) 2016-08-03
TWI650127B (zh) 2019-02-11
WO2015105135A1 (ja) 2015-07-16
MX385505B (es) 2025-03-18
US20160317664A1 (en) 2016-11-03
TW201609097A (zh) 2016-03-16
US20190060459A1 (en) 2019-02-28
IL246655B (en) 2020-05-31
ES2875307T3 (es) 2021-11-10
MX2020003133A (es) 2021-08-23
HK1224190A1 (zh) 2017-08-18
US10149908B2 (en) 2018-12-11
SG11201605366QA (en) 2016-08-30
EP3093019A4 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
MX2016009049A (es) Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
MX2016009058A (es) Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
MX2018014116A (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil )pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirroli din-1-carboxamida y sales del mismo.
AR108768A2 (es) Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CL2013002737A1 (es) Acido 4-((4-((((1r, 2s)-2-fenilciclopropil)amino)metil)piperidin-1-il)metil)benzoico con actividad inhibidora de desmetilasa 1 especifica de lisina (lsd1); composicion farmaceutica que lo comprende, utiles en el tratamiento del cancer.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
MX349712B (es) Moduladores del transporte nuclear que contienen hidrazida y sus usos.
CL2018000249A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
AR103680A1 (es) Inhibidores selectivos de bace1
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
MX2020005735A (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
MX2016010083A (es) Composicion farmaceutica para administracion topica.
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
MX2015009617A (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
AR090592A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"